Nebenwirkungen · Trelegy Ellipta
Trelegy Ellipta 92 micrograms/55 micrograms/22 micrograms inhalation powder, pre-dispensed · Abschnitt 4.8 · PDF-Seite 8
HOS-138236 · Präparat HOS-098164
Pneumonia In a total of 1 810 patients with advanced COPD (mean post-bronchodilator screening FEV1 45% of predicted, standard deviation (SD) 13%), 65% of whom had experienced a moderate/severe COPD exacerbation in the year prior to study entry (study CTT116853), there was a higher incidence of pneumonia events reported up to 24 weeks in patients receiving Trelegy Ellipta (20 patients, 2%) than in patients receiving budesonide/formoterol (7 patients, <1%). Pneumonia which required hospitalisation occurred in
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-08T12:00:00Z · SHA-256 da8a456ad1e55d2f32bd6c089e4b8c46019bb784e9ff1f604d031e5d487eea91 · Passage 1f4e4a481b8bc8949ebf21701b46c251ccdc53bb096ef77dde76619c90ac1133 · Zeichen 3563–4075 im Abschnitt